- Home
- SSRM vs BLTE Comparison
SSRM vs BLTE Comparison
Compare SSRM & BLTE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SSRM
- BLTE
- Stock Information
- Founded
- SSRM 1946
- BLTE 2018
- Country
- SSRM United States
- BLTE United States
- Employees
- SSRM N/A
- BLTE N/A
- Industry
- SSRM Precious Metals
- BLTE Biotechnology: Pharmaceutical Preparations
- Sector
- SSRM Industrials
- BLTE Health Care
- Exchange
- SSRM Nasdaq
- BLTE Nasdaq
- Market Cap
- SSRM 2.2B
- BLTE 2.1B
- IPO Year
- SSRM 1996
- BLTE 2022
- Fundamental
- Price
- SSRM $13.16
- BLTE $56.81
- Analyst Decision
- SSRM Hold
- BLTE Strong Buy
- Analyst Count
- SSRM 3
- BLTE 4
- Target Price
- SSRM $10.53
- BLTE $96.67
- AVG Volume (30 Days)
- SSRM 3.3M
- BLTE 44.5K
- Earning Date
- SSRM 07-30-2025
- BLTE 08-08-2025
- Dividend Yield
- SSRM N/A
- BLTE N/A
- EPS Growth
- SSRM N/A
- BLTE N/A
- EPS
- SSRM 0.42
- BLTE N/A
- Revenue
- SSRM $1,082,002,000.00
- BLTE N/A
- Revenue This Year
- SSRM $40.21
- BLTE N/A
- Revenue Next Year
- SSRM $19.05
- BLTE N/A
- P/E Ratio
- SSRM $30.53
- BLTE N/A
- Revenue Growth
- SSRM N/A
- BLTE N/A
- 52 Week Low
- SSRM $4.32
- BLTE $43.70
- 52 Week High
- SSRM $13.46
- BLTE $86.53
- Technical
- Relative Strength Index (RSI)
- SSRM 61.30
- BLTE 38.05
- Support Level
- SSRM $12.04
- BLTE $59.00
- Resistance Level
- SSRM $12.67
- BLTE $59.71
- Average True Range (ATR)
- SSRM 0.48
- BLTE 2.15
- MACD
- SSRM -0.05
- BLTE -0.40
- Stochastic Oscillator
- SSRM 78.87
- BLTE 10.92
About SSRM SSR Mining Inc.
SSR Mining Inc is a minerals company focused on mining precious metals in the Americas. More than half of Silver Standard's revenue is attributable to the production of gold, with a key portion derived from silver production. The company owns and operates the Marigold mine in Nevada, United States; the Seabee Gold Operation in Saskatchewan, Canada; and the Puna mine in Argentina. The majority of gold production is derived from the Marigold mine, and Silver Standard's silver production is principally derived from the Puna mine.
About BLTE Belite Bio Inc
Belite Bio Inc is a clinical-stage biopharmaceutical drug development company focused on novel therapeutics targeting untreatable eye diseases involving retinal degeneration such as atrophic age-related macular degeneration and autosomal recessive Stargardt disease or STGD1, both of which progressively to permanent blindness, and metabolic diseases such as non-alcoholic fatty liver disease, or NAFLD, nonalcoholic steatohepatitis, or NASH, type 2 diabetes, or T2D, and gout.